Becton Dickinson & (BDX) Stock
Global medical technology firm supplying devices and instruments. Here's the price, business snapshot, and what's worth knowing about Becton Dickinson & in July 2026.
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It’s Moving
BDX is drawing steady analyst support as investors focus on dependable healthcare demand, not a sudden catalyst.
- Analyst sentiment around BDX has stayed constructive, with several firms maintaining positive ratings and mid-200s price targets, reinforcing the view that the company’s earnings power remains solid.
- The wider forecast range is still broad, which suggests investors are weighing steady healthcare demand against slower growth in parts of the business rather than betting on a sharp catalyst.
- Recent commentary points to a stock that is being valued more on stable execution and defensive characteristics than on a near-term breakout, which can help explain why upside expectations remain measured.
BDX is drawing steady analyst support as investors focus on dependable healthcare demand, not a sudden catalyst.
- Analyst sentiment around BDX has stayed constructive, with several firms maintaining positive ratings and mid-200s price targets, reinforcing the view that the company’s earnings power remains solid.
- The wider forecast range is still broad, which suggests investors are weighing steady healthcare demand against slower growth in parts of the business rather than betting on a sharp catalyst.
- Recent commentary points to a stock that is being valued more on stable execution and defensive characteristics than on a near-term breakout, which can help explain why upside expectations remain measured.
When is the next earnings date for BECTON DICKINSON & CO (BDX)?
BDX’s next earnings date is currently expected around August 6, 2026, though some sources show a narrower window from late July to early August and the company has not formally confirmed the date. The report should cover Q3 2026 results. Based on BDX’s historical cadence, an earnings release in early August is the most consistent expectation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton, Dickinson and Company's stock, expecting it to rise in value.
Financial Health
Becton, Dickinson and Company is showing strong revenue and profits, with solid cash generation capabilities.
Dividend
Becton, Dickinson and Company's dividend yield of 2.42% offers a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $41.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring BDX
Drug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
